-
Psoriasis (Event Driven)
Pharmacor, 2010
Last Updated 3 September 2010
Despite the major impact psoriasis has on patients’ quality
of life, physicians believe many patients are untreated or...
-
Pharmaceutical Pricing, Reimbursement, and Market Access News in the Second Quarter of 2010
Advisory Service, September, 2010
The second quarter of 2010 built on an exceptionally
eventful first quarter with regard to pharmaceutical pricing, reimbursement,
and market access. The U.S....
-
Asthma (Event Driven)
Pharmacor, 2010
Last Updated 2 September 2010
With a large and growing patient population, the asthma
market is one of the most lucrative drug markets in the...
-
Alzheimer's Disease (Event Driven)
Pharmacor, 2010
Last Updated 2 September 2010
Despite a large and rapidly growing patient population, the
treatment of Alzheimer’s disease (AD) consists only of...
-
Fibromyalgia (Event Driven)
Pharmacor, 2010
Last Updated 2 September 2010
Fibromyalgia affects an estimated 16 million people across
the major pharmaceutical markets and is one of the most...
-
Parkinson's Disease (Event Driven)
Pharmacor, 2010
Last Updated 1 September 2010
Parkinson’s disease (PD) is one of the most common chronic
neurodegenerative diseases in the elderly. The PD therapy...
-
Colorectal Cancer (Event Driven)
Pharmacor, 2010
In 2009, colorectal cancer (CRC) was the third-most
diagnosed cancer in the United States. We expect the number of incident cases
of CRC to increase between...
-
Chronic Obstructive Pulmonary Disease (Event Driven)
Pharmacor, 2010
Last Updated 30 August 2010
The sizeable therapeutic market for chronic obstructive
pulmonary disease (COPD), a disease that is closely affiliated...
-
Human Immunodeficiency Virus (HIV) (Event Driven)
Pharmacor, 2010
Last Updated 26 August 2010
The HIV market is highly dynamic, with one of the most
active pipelines, significant investment in R&D, and continually...
-
Will Emerging MAbs Threaten MabThera’s Domination of the Non-Hodgkin’s Lymphoma and Chronic Lymphocytic Leukemia Markets in Europe? Clinician and Payer Perspectives
European Physician & Payer Forum, August, 2010
The current treatment of non-Hodgkin’s
lymphoma (NHL) and chronic lymphocytic leukemia (CLL) is characterized by the
high uptake of MabThera (Roche’s...
-
Osteoporosis (Event Driven)
Pharmacor, 2010
Last Updated 24 August 2010
Osteoporosis and osteopenia raise the risk of suffering a
fracture. Fractures are a substantial public health and...
-
Prostate Cancer (Event Driven)
Pharmacor, 2010
Last Updated 23 August 2010
Prostate cancer (CaP) was the leading cause of new cancer
cases and the second highest cause of cancer-related deaths...
-
Bipolar Disorder (Event Driven)
Pharmacor, 2010
Last Updated 23 August 2010
Bipolar disorder (BPD) is a chronic and debilitating
psychiatric illness. Found across all major pharmaceutical markets,...
-
Brand Perception Series: Physician Segmentation in Asthma
Brand Perception Series: Physician Segmentation, August, 2010
An analysis of primary research
conducted with 239 U.S. physicians reveals four key segments of physicians who
treat asthma patients, differentiated by the...
-
Irritable Bowel Syndrome (Event Driven)
Pharmacor, 2010
Last Updated 23 August 2010
Although a highly prevalent condition, irritable bowel
syndrome (IBS) is marked by low diagnosis and treatment rates in...
-
Liver Cancer in China
Emerging Markets, August, 2010
China is one of the most rapidly growing pharmaceutical
markets in the world. Currently, China’s newly diagnosed incident cases of
hepatocellular carcinoma...
-
Special Report: 2010 Chartbook of International Pharmaceutical Prices
Spectrum, August, 2010
Payers in all countries are increasing their pressure on manufacturers
to cut prices. But prescription drug pricing and reimbursement policies vary
markedly...
-
Treatment Algorithms in Asthma
Treatment Algorithms, August, 2010
Although classes of rescue and maintenance therapies used to
treat patients with asthma are well-established in the treatment algorithm,
recent disruptions...
-
Executing Change: Survival Strategies of Big Biotech
Spectrum, August, 2010
Economic pressures have forced Big Biotech companies to
reevaluate their business strategies in order to minimize costs and prioritize
therapy areas that will...
-
SPECIAL REPORT: Dealmaking and Industry Outlook in Niche Metabolic Diseases
Spectrum, August, 2010
Pharmaceutical companies should take a keener interest in
developing therapies for niche metabolic diseases. Biologics will enjoy 12
years of marketing...